I got involved in the biotech sector in 2004 because I realized that no other sector had the same potential for enormous gains and sustained growth.
You’ve probably heard the stats by now. Ten thousand baby boomers turn 65 every day in the United States. And what do we consume more of as we get older? Healthcare.
As we advance in our senior years, more people get sick and require more medicines for difficult-to-treat diseases.
So if I could invest in only one sector for the next five or 10 years, it would be biotech. But how do you choose which ones to invest in?
As The Oxford Club’s resident biotech expert, I’m often asked what I look for when choosing biotech stocks.
Here are some of the things I want to see:
I’m not interested in a company that has a cancer drug that adds two months of life over the existing standard of care. I want to see entirely new approaches to treating disease – something we’ve never seen before.
A drug is unlikely to get approved if it is unsafe, no matter how effective it is. I pay particularly close attention to Phase 2 trial results because that’s usually the first real indication of whether a drug is safe enough to try in a larger population.
Biotech stocks can move quickly on news. I don’t want to be sitting with a stock for a year and a half waiting for clinical trial results. I typically want to see important trial data within six months.
Cash on the books.
Most small cap biotech companies are unprofitable and burn cash. I’d rather not be holding the stock when management sells shares to raise capital. This dilutes existing shareholders and causes the stock to drop. If the company has a lot of cash already, it reduces the chance of seeing a stock offering.
I like to see investors who I respect own large holdings in the stock. When I see investors like Felix and Julian Baker or others, I know some major league brainpower has reviewed the company’s science and investment opportunity ahead of me and has decided to move forward. My confidence is also boosted when insiders own a lot of shares.
From there, I’ll dig into the clinical trials, investigate management to see whether there are any red flags and conduct other due diligence.
There are a lot of factors that go into deciding to pull the trigger on a biotech stock, but the above list is a good start.
Remember, no other sector sees stocks move 50% or even more than 100% in a day on a takeover announcement.
Five Prime Therapeutics (Nasdaq: FPRX) was up 78% in one day in March on an acquisition announcement – and that was after it jumped 349% in one day in November after reporting positive data.
I would argue that biotech is the most important sector in the market and will be for the next five to 10 years and beyond. Your portfolio should have some exposure to it in order to take advantage of the enormous potential.